Bausch Health Announces 2026 Gastrointestinal Health Scholars Program
Rhea-AI Summary
Bausch Health (NYSE: BHC) and its gastroenterology business Salix opened applications for the 2026 Salix Gastrointestinal Health Scholars Program. The program will award 10 scholarships of up to $10,000 to students living with GI disease for the 2026–2027 academic year. Applications close May 6, 2026, and recipients will be notified in summer 2026. Awards include undergraduate, graduate, and working/single-parent categories. Applicants must submit an online application, references, and an essay about their GI condition and a health care provider's role. More details and eligibility are available at the Salix scholarship webpage.
Positive
- None.
Negative
- None.
News Market Reaction – BHC
In the Feb 11 session, BHC declined 1.30%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 23 | Phase 3 trial update | Negative | -10.1% | Phase 3 RED-C program missed primary endpoint in hepatic encephalopathy. |
| Jan 21 | Earnings date set | Neutral | -2.1% | Announced date and call details for Q4 and full-year 2025 results. |
| Jan 05 | Conference participation | Positive | +2.6% | Management presenting strategic update at J.P. Morgan Healthcare Conference. |
| Dec 23 | Debt exchange results | Neutral | -1.9% | Final results of exchanges into 10.00% Senior Secured Notes due 2032. |
| Dec 08 | Early exchange update | Neutral | -0.3% | Reported early tender results for 2028 notes into new 2032 notes. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent identifiable catalysts (a Phase 3 trial miss and conference participation) both saw price moves that aligned with the news tone, suggesting the stock has reacted directionally in line with major developments.
Over the last few months, Bausch Health has focused on clinical and balance sheet developments. On Jan 23, 2026, a Phase 3 RED-C trial missed its primary endpoint, and the stock fell 10.05%. Earlier, the company highlighted its upcoming Q4/FY 2025 earnings date and participation in the J.P. Morgan Healthcare Conference, with the conference update coinciding with a 2.64% gain. Late 2025 was dominated by debt exchange offers and new 2032 senior secured notes, which drew relatively modest price moves. Today’s scholarship announcement is more reputational than financial, fitting a pattern of varied news intensity.
Key Terms
gastroenterology medical
gi medical
liver diseases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases
"Bausch Health is honored to offer The Salix Gastrointestinal Health Scholarship for the seventh consecutive year. This scholarship financially supports students who are driven to persevere through their GI disorders and liver diseases while still maintaining academic excellence. Salix's commitment to support these patients and make a difference in the lives of all communities we serve remains a top priority," said Aimee Lenar, Executive Vice President,
Students can apply for this scholarship by completing the online application, submitting letters of reference, and writing an essay on the impact having a diagnosed GI condition has had on their life and the role that a health care provider played in helping to manage their condition. Scholarships are offered to school applicants or current attendees of a two- or four-year college, university, or an advanced (post-high school) vocational or technical school for the 2026-2027 academic year and are available in the following categories:
- Undergraduate Scholar Awards for students pursuing undergraduate degrees.
- Graduate Scholar Awards for students pursuing graduate degrees.
- Working and/or Single Parents Scholar Award for students who are working parents and/or single parents pursuing undergraduate, vocational/technical or graduate degrees.
The application period for the Salix Gastrointestinal Health Scholars Program will close on May 6, 2026, and scholarship recipients will be notified in the summer of 2026. To learn more about the scholarship, including eligibility criteria, terms and conditions, please visit www.salix.com/scholarship.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
©2026 Salix Pharmaceuticals or its affiliates.
BHC-ORGANIZATION | |
Investor Contact: | Media Contacts: |
Garen Sarafian | Katie Savastano |
877-281-6642 (toll-free) | (908) 569-3692 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-announces-2026-gastrointestinal-health-scholars-program-302682672.html
SOURCE Bausch Health Companies Inc.